ADULT AIDS CLINICAL TRIALS UNIT

  • Pollard, Richard B (PI)
  • Ahmed, Ahmed (PI)
  • Nokta, Mostafa (PI)
  • Stanberry, Lawrence (PI)
  • O'Brien, William Austin (PI)

Project: Research project

Description

This ACTU site plans to continue to be an active participant in HIV
clinical trials. One hundred patients per year emphasizing earlier phase
trials will be enrolled. It is proposed that this site will enroll 15
patients per year into phase I studies, 20 patients per year into phase
I/II studies, 25 patients per year in phase II studies, and 40 patients per
year into phase III clinical trials. The focus of the investigations will
be influenced by the nature of the patients seen at the institution and
available for ACTG supported studies. This patient population is ideal for
the study of primary antiretroviral therapy in patients with advanced
disease or for studies of newer agents for opportunistic infections. The
number of patients is anticipated to continue to grow, making this
institution capable of enrolling patients in multiple clinical trials. The principal focus of primary infection studies will be on newer
therapies, particularly in advanced disease. Phase I and/or phase I/II
studies in such patients are planned followed by combination therapies.
Combining immunomodulators with primary antiretroviral studies is proposed. Studies in opportunistic infections will concentrate on the development of
new agents for acute infections. The Gastroenterology and Pulmonary
collaborators will facilitate studies of new therapies involving those
organ systems. The Oncology co-investigator will facilitate studies of the therapy for
HIV-associated malignancies. The Neurology collaborator will guide
participation in studies of therapies aimed at neurologic complications of
HIV infection or opportunistic infections involving the nervous system. Development of a collaborative group from multiple disciplines which will
focus on development of new therapies for HIV infection and opportunistic
infection will provide a broad range of expertise. Innovative protocol
development will be a priority of this study group whose goal is to improve
therapeutic options available to patients as quickly as possible.
StatusFinished
Effective start/end date4/1/923/31/08

Funding

  • National Institutes of Health: $1,882,971.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $1,673,531.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health: $1,842,655.00
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health
  • National Institutes of Health

Fingerprint

Opportunistic Infections
Acquired Immunodeficiency Syndrome
HIV
Clinical Trials
Therapeutics
Neurology
Nervous System
Allergy and Immunology
Virology
Infection
Women's Health
Phase III Clinical Trials
Immunologic Factors
HIV Infections
Research
Gastroenterology
Cytomegalovirus
Research Personnel
Antiviral Agents
Pharmacology

ASJC

  • Medicine(all)
  • Immunology and Microbiology(all)